Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology.

Molecular pharmacology - 10 Jan 2024

Kim Justin J, Schaeffner Ilse K, Heppner David E, To Ciric, Jänne Pasi A, Beyett Tyler S, Eck Michael J

Abstract excerpt

Lung cancer is commonly caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric kinase inhibitors are unaffected by common ATP-site resistance mutations and represent a promising therapeutic strategy for targeting drug-resistant EGFR variants. However, allosteric inhibitors are antagonized by kinase dimerization, and understanding this phenomenon has been limited to cellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to F3 gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38164587
DOI: 10.1124/molpharm.123.000768
PMCID: PMC10794983

Genes

EGFR
F3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology.PMID 38164587Read ↗

Mechanistic insights into the activation of oncogenic forms of EGF receptor.Semantic proximity Read ↗

EGFR Oncogenes Expressed In Glioblastoma Are Activated As Covalent Dimers And Paradoxically Stimulated By ErlotinibSemantic proximity Read ↗

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.Semantic proximity Read ↗

The role of kinase domain dimerization in EGFR activation.Semantic proximity Read ↗

Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers.Semantic proximity Read ↗

Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Semantic proximity Read ↗

Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations.Semantic proximity Read ↗

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.Semantic proximity Read ↗

Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase.Semantic proximity Read ↗

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors.Semantic proximity Read ↗

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.Semantic proximity Read ↗

Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.